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Abstract
The present study was undertaken to investigate whether Neamon-Hepa treatment provides antioxidant protection from chronic liver 
injury induced in mice by a long-term CCl4 administration.  The Neamon-Hepa capsule, a combination indigene drug, contains L-arginine, 
Spironolactone and biopreparation from the Spirulina platensis - BioR.  Carbon tetrachloride chronic treatment for three weeks significantly 
decreased the hepatic antioxidant enzyme activities - almost twofold superoxide dismutase enzyme activity, catalase activity, glutathione peroxidase 
activity in liver tissue and induced a marked elevation almost twofold of thiobarbituric acid reactive substances levels in the plasma and liver 
tissue.  Treatment with the Neamon-Hepa following experimental liver damage, in a dose-dependent way, resulted in a marked augmentation 
of antioxidant enzyme activities and reduction of lipid peroxidation levels.
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Антиоксидантные возможности фармацевтического препарата Неамон-Хепа при токсическом гепатите, индуцированным 
тетрахлоридом углерода
Целью данной работы является исследование антиоксидантного воздействия  лекарственного препарата Неамон-
Хепа у мышей с токсическим гепатитом, индуцированным тетрахлоридом углевода.  В состав комбинированного 
медикамента Неамон-Хепа входит аргинина аспартат, БиоР и спиронолактон.  Хроническая интоксикация в течении 
3 недель с ССl4 снизила в два раза активность супероксиддисмутазы, каталазы, глутатионпероскидазы  в печеночной 
ткани и повысила вдвое степень тиобарбитуровой  кислоты в печеночной ткани и в сыворотке крови.  Применение 
препарата Неамон-Хепа значительно уменьшило степень процессов липидного пероксидирования и увеличило актив-
ность антиоксидативных энзимов.
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Introduction
The liver has versatile functions and plays several impor-
tant roles in metabolism, including biosynthesis of plasma 
proteins, gluconeogenesis and detoxification.  Although the 
liver has strong regenerative ability, when cellular loss exceeds 
a certain threshold, the insufficient functions cause hepatic 
failure, leading to liver disease.
Oxidative and nitrosative stress are common pathogenetic 
mechanisms contributing to the initiation and progression of 
hepatic damage in a variety of liver disorders.  Highly reac-
tive transient chemical species, i.e., superoxide anion (O2.−), 
hydrogen peroxide (H2O2), hydroxyl radical (. OH), singlet 
oxygen (1O2) and nitric oxide (.NO), have been implicated in 
the aetiology of degenerative diseases, including some hepa-
topathies [1].  These molecules, which are the byproducts of 
normal aerobic metabolism, are highly reactive and thus lead 
to the denaturation of biomolecules such as proteins, lipids 
and nucleic acids, resulting in injury to cells, tissues and or-
gans.  Cell damage occurs when there is an excess of reactive 
species or a defect of antioxidant molecules.  Experimental 
research on the delicately regulated molecular strategies whe-
reby cells control the balance between oxidant and antioxidant 
molecules has progressed in recent years [2, 3].  On the basis 
of this evidence, antioxidants represent a logical therapeutic 
strategy for the treatment of chronic liver disease.
Carbon tetrachloride (CCl4) is a well established and widely 
used hepatotoxin and the principle cause of CCl4-induced liver 
injury is proposed to be lipid peroxidation by free radical deriva-
tives of CCl4.  In the liver, CCl4 is rapidly metabolized by mixed 
function cytochrome P450 oxygenases of the endoplasmic re-
ticulum resulting in the generation of the trichloromethyl radical 
(CCl3˙).  This radical can also react with oxygen to form its highly 
reactive derivative trichloromethyl peroxy radical (CCl3OO˙). 
Both radicals initiate a chain reaction leading to lipid peroxida-
tion, changes in membrane permeability, and loss of calcium 
homeostasis.  In addition, tissue lipid levels increase.  The initial 
cellular injury subsequently takes the form of inflammation, 
and the chronic effects of CCl4 exposure include fatty degenera-
tion and fibrosis that may ultimately culminate in extensive cell 
damage and death [4].
Neamon-Hepa is a multicomponent pharmaceutical 
product thought to have hepatoprotective properties and 
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can prevent the progression of chronic liver diseases.  The 
Neamon Hepa capsule contains L-arginine, Spironolactone 
and biopreparation from the Spirulina platensis - BioR.  In 
a previous study we have shown that treatment of mice with 
the Neamon Hepa concomitant with the CCl4 produced an 
alleviation of the hepatic injury to a considerable extent which 
was reflected by the ability of the compound to lower the el-
evated liver/body weight index and the raised serum enzyme 
activities resulting from the administration of CCl4 alone [5].
The present study was undertaken to investigate whether 
Neamon Hepa treatment provides antioxidant protection 
from chronic liver injury induced by a long-term CCl4 ad-
ministration.
Material and Methods
Male C57/Bl6 mice, aged 12 weeks and weighing 27-30 g, 
were used in the present study.  The animals were housed ac-
cording to our institution’s animal-care guidelines. The cages 
were placed in ventilated closed rack at constant temperature 
and humidity with a 12-hour light/dark cycle.  They were fed 
using commercially standard mouse diet and sterilized water 
ad libitum. 
Mice were divideded into the following five study groups:
Control (n = 6);
CCl4  (n = 6);
CCl4 received Neamon-Hepa 10 mg/kg (n = 6);
CCl4 received Neamon-Hepa 50 mg/kg (n = 6);
CCl4 received Neamon-Hepa 100 mg/kg (n = 6);
Animals received an subcutaneos 1 ml/kg injection of CCl4 
(Sigma) in sesame oil (1:1 ratio) twice weekly (Monday and 
Thursday) for three weeks.  Control animals were injected 
with an equivalent amount of sesame oil.  Neamon-Hepa 
(Eurofarmaco SA) capsules (834 mg) were dissolved initialy in 
4.2 ml etanol and then removed from it (ex. 168 µl for group 
V) was added in to 100 ml of drinking water.
Subsequently, on the fifth day after last CCl4 injection, the 
mice of each group were sacrificed by exsanguination, the 
blood was collected and plasma was separated from it and 
frozen for laboratory tests.  Livers were quickly excised under 
ice-cold conditions.  A portion of the liver was thoroughly 
washed three times with saline to remove maximal possible 
residual blood.  The samples were frozen and stored at -70ºC 
until  analysis.
Lipid peroxidation was estimated by measurement of thio-
barbituric acid reactive substances (TBARS) in the liver tissue 
by the method of Uchiyama and Mihara [6]. Plasma TBARS 
level were measured according to the method of Buege and 
Aust [7].  It is expressed as micromoles per liter for plasma 
and as micromoles per gram weight liver tissue.
Superoxide dismutase (SOD) enzyme activity was analyzed 
according to the method of Beauchamp and Fridovich [8]. 
Catalase (CAT) activity was estimated by the procedure of 
Thomson et al. [9].  Glutathione peroxidase (GPx) activity 
was measured by the method of Paglia and Valentine [10]. 
SOD, CAT and GPx activities were expressed as international 
units per milligram protein.
Results are presented as means ± standard error of the 
mean (SEM).  Comparisons between groups were carried 
out using t-test.  Differences with P < 0.05 were regarded as 
statistically significant.
Results
Carbon tetrachloride chronic treatment significantly 
decreased the hepatic antioxidant enzyme activities.  The 
SOD, CAT, and GPx activities in CCl4-treated mice were 
52.1%, 57.4% and 66.6% respectively, compared to the con-
trol mice.  At the same time, CCl4 chronic treatment induces 
a marked elevation of TBARS levels, which were assessed as 
an indicator of lipid peroxidation.  The level of TBARS were 
more than twofold greater in the plasma and liver tissue from 
CCl4-treated group.
Treatment with the Neamon-Hepa following experimental 
liver damage resulted in a marked augmentation of antioxi-
dant enzyme activities and reduction of lipid peroxidation 
levels.  As is shown in the table, the most consistent evidence 
for beneficial effects came from a maximal daily dosage of 
Neamon-Hepa.  All doses of Neamon-Hepa increased the 
decreased antioxidant enzyme activities in CCl4-treated mouse 
liver.  This effect was dose dependent, with the highest level 
of antioxidant enzymes activities occurring in the group that 
received Neamon-Hepa 100 mg/kg.  For example, in this group 
SOD, CAT and GPx activities increased more than 65%, 55% 
and 30% respectively, compared to the CCl4-treated group. 
On the other hand, dose-dependent treatment with Neamon-
Hepa significantly decreased the increased level of TBARS 
in both the plasma and liver tissue.  As a result, treatment 
Table 1
Effects of Neamon-Hepa on antioxidant enzymes (SOD, CAT, GPx) activities in the liver  
and TBARS in the liver and plasma of CCl4-treated and control mice
Group SOD(U/mg protein)
CAT
(U/mg protein)
GPx
(U/mg protein)
TBARS
Liver
(µM/g tissue)
Plasma
(µM/L)
I 25.7 ± 0.96 18.8 ± 0.80 11.1 ± 0.52 0.48 ± 0.05 0.24 ± 0.02
II 13.3 ± 1.55# 10.8 ± 0.72# 7.4 ± 0.52# 1.27 ± 0.08# 0.62 ± 0.09#
III 16.8 ± 0.90* 14.2 ± 0.87* 7.9 ± 0.25 1.03 ± 0.06* 0.40 ± 0.08*
IV 19.4 ± 0.85** 15.8 ± 0.83** 8.9 ± 0.35* 0.84 ± 0.05** 0.36 ± 0.08*
V 22.3 ± 1.18** 17.0 ± 0.55** 9.7 ± .37** 0.67 ± 0.06** 0.32 ± 0.07**
The values are mean ± S.D. 
# p < 0.01, as compared to the control group; 
* p < 0.05, ** p < 0.01, as compared to the second group. 
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with 100 mg/kg of Neamon-Hepa decreased TBARS levels 
from 90% to 70% in the liver tissue and plasma respectively 
compared to CCl4-treated mice.  Although, CCl4-induced 
lipid peroxidation effcts were significantly attenuated by 
Neamon-Hepa treatment, value were still higher than those 
found in the control group.
Discussion
The antioxidant activity of Neamon-Hepa was measured 
by its protection against CCl4-induced liver damage in mice. 
Liver damage induced by carbon tetrachloride is the best 
characterized system of xenobiotic-induced hepatotoxicity 
and is a commonly used model for the screening of in vivo 
antioxidant and hepatoprotective activity of drugs.  Several 
mechanisms underlying this toxicity have been suggested. 
The hepatotoxic effects of CCl4 are largely due to its active 
metabolite, trichloromethyl radical.  These activated radicals 
bind covalently to the macromolecules and induce peroxidati-
ve degradation of membrane lipids of endoplasmic reticulum 
rich in polyunsaturated fatty acids.  This leads to the formation 
of lipid peroxides.  This lipid peroxidative degradation of bi-
omembranes is one of the principle causes of hepatotoxicity 
of CCl4 [4, 11]. 
Previously, we have shown that Neamon-Hepa treatment 
decreased CCl4-induced liver damage in mice.  The activity of 
serum alanine aminotransferase, aspartate aminotransferase 
and level of total bilirubin decreased more than twofold in the 
group of animals that received 100 mg/kg of Neamon-Hepa 
daily.  At the same time, we found a marked lowering of cho-
lesterol level, lactate dehydrogenase and alkaline phosphatase 
activities [5]. 
In the present investigation, exposure to chronic doses of 
CCl4 caused decreases in the hepatic SOD, CAT and GPx ac-
tivities.  The glutathione-dependent enzymes SOD, CAT, and 
GPx represent co-ordinately regulated major cellular defense 
systems against oxidative stress.  Glutathione content in the 
liver contributed to the maintenance of cell homeostasis by 
scavenging free radicals resulting from physical or chemical 
injuries. It has been suggested that the lipid peroxides gen-
erated after CCl4 intoxication are eliminated by GPx in the 
presence of glutathione, thus curbing the propagation of 
lipid peroxidation [12].  In our experiments, the significant 
decrease in hepatic GPx activity following CCl4 exposure was 
partially restored by Neamon-Hepa therapy. 
SOD has been reported as one of the most important en-
zymes in the enzymatic antioxidant defense system.  Decrease 
in enzyme activity of SOD is a sensitive index in hepatocel-
lular damage and is the most sensitive enzymatic index in live 
injury [13].  SOD acts as a cellular deference element against 
potentially harmful effects of superoxide ions by catalyzing 
the dismutation of these ions.  Superoxide radical is one of the 
main causes of oxygen cytotoxicity, for it is the first oxygen 
radical produced in vivo, and lasts for longer time than other 
radicals.  Simultaneously, Neamon-Hepa treatment causes a 
significant increase in hepatic SOD activity; more than 65% 
in the group that received a higher dose. 
Cathalase is a haemoprotein and it protects cells from the 
accumulation of hydrogen peroxide by dismutating it to from 
N2O and O2 or by using it as an oxidant in which it works as a 
peroxidase [14].  A large reduction in the CAT activity in our 
CCl4-treated mice may result in a number of deleterious effects 
due to the assimilation of superoxide radical and hydrogen 
peroxide.  In contrast, administration of Neamon-Hepa show 
a significant dose-dependent increasing in CAT activity.  Liver 
TBARS level is considered to be a valuable indicator of toxicant 
induced hepatic damage from production of free radicals [14]. 
Elevated level of TBARS observed in our CCl4-treated mice 
indicates excessive formation of free radicals and activation 
of lipid peroxidation system resulting in hepatic damage.  The 
significant decline in the concentrations of these constituents 
in the liver and plasma of Neamon-Hepa-treated mice unveils 
its antioxidant efficacy.  We suppose that all three essential 
components L-arginine, Spironolactone and BioR (bioprepa-
ration from the Spirulina platensis) inserted in the Neamon-
Hepa together are able to increase antioxidant activity and to 
lower TBARS levels.
It has been reported that the use of Spironolactone in 
the combined therapy effectively attenuates oxidative stress 
in patients with chronic kidney disease [15] and prevents 
oxidative stress in uremic rats [16].  Also, it was shown that 
intervention with antioxidants and l-arginine reduced the 
activation of redox-transcription factors and increased eNOS 
expression in cells and in vivo [17, 18].
The antioxidant property of various Spirulina platensis 
extracts under CCl4-induced hepatic damage had been repor-
ted [19, 20].  Recently, new experimental data were presented 
on the influence of the complexes of Fe(III), Mn(II), Zn(II), 
Co(II) on the synthesis of antioxidants in the biomass of 
spirulina and dunaliella.  Simultaneously, they define a new 
procedure for obtaining antioxidant preparations on the 
basis of spirulina’s and dunaliella’s biomass [18].  Further 
studies find a significant decline in malondialdehyde, lipid 
hydroperoxides and conjugated dienes with rise in SOD, 
catalase, GPx, glutathione, vitamin-E and vitamin-C levels 
in the hepatic and renal tissues when rats were given therapy 
with purified cyanobacterial phycoerythrin together with 
CCl4 intoxication for 4 weeks [19].  A more detailed scientific 
report confirms the fact that Phycocyanin, a biliprotein from 
Spirulina platensis is a potential therapeutic agent in oxidative 
stress-induced diseases.  Furthermore, it was able to scavenge 
alkoxyl, hydroxyl and peroxyl radicals and to react with pero-
xinitrite and hypochlorous acid. It also inhibits microsomal 
lipid peroxidation induced by Fe+2-ascorbic acid or the free 
radical initiator 2,2’ azobis (2-amidinopropane) hydrochlo-
ride in vitro and  reduces CCl4-induced lipid peroxidation 
in vivo [20].
In conclusion, the results in this study indicate that 
Neamon-Hepa treatment can ameliorate CCl4 stress-indu-
ced oxidative liver injury.  Nevertheless, further research 
must be carried out to elucidate the mechanisms of the 
hepatoprotective antioxidant effect by Neamon-Hepa at 
the molecular level.
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The Spectrum of Mesenchymal Tumors of the Skin
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The Spectrum of Mesenchymal Tumors of the Skin
Cutaneous tumours of mesenchymal origin are relatively uncommon tumors, originating from non-epithelial skin structures and 
characterized by clinico-pathological heterogeneity.  Being classified histologically according to the mature tissue they resemble, 
these heterogeneous mesenchymal neoplasms show a broad range of differentiation and form the largest group of skin tumors.  The 
aim of the study was to analyze the incidence patterns and clinical peculiarities of cutaneous mesenchymal tumours according to the 
histologic type.  Research trials were conducted in the Institute of Oncology of the Republic of Moldova and included 1121 patients 
with cutaneous tumors of mesenchymal origin, surgically treated in the period 2004-2008, including 1036 (92.4%) benign tumors 
and 85 (7.6%) malignant tumors.  The most frequent benign tumors were hemangioma (52.4%) and dermatofibroma (33.7%).  Kaposi 
sarcoma was the most common form of cutaneous malignant mesenchymal tumors, accounting for 43.53% of cases. 41.18% of skin 
tumors of mesenchymal origin were reprezented by dermatofibrosarcoma protuberans, which is a locally aggressive tumor with a high 
recurrence rate and little metastatic potential.  This study demonstrated variation by age, sex and anatomic location in patients with 
cutaneous sarcomas according to the histologic type.
Key words: cutaneous mesenchymal tumors, Kaposi sarcoma, dermatofibrosarcoma protuberans.
